Phase II study of cisplatin/pemetrexed combined with bevacizumab followed by pemetrexed/bevacizumab maintenance therapy in patients with EGFR-wild advanced non-squamous non-small cell lung cancer
Sign Up to like & getrecommendations! Published in 2018 at "Cancer Chemotherapy and Pharmacology"
DOI: 10.1007/s00280-018-3573-0
Abstract: PurposeThis phase II study was performed to evaluate the efficacy and safety of cisplatin/pemetrexed combined with 15 mg/kg of bevacizumab followed by pemetrexed/bevacizumab maintenance therapy as first-line chemotherapy in advanced non-squamous non-small cell lung cancer (NSCLC)… read more here.
Keywords: maintenance therapy; egfr wild; maintenance; followed pemetrexed ... See more keywords
A multifunctional nanotheranostic agent potentiates erlotinib to EGFR wild-type non-small cell lung cancer
Sign Up to like & getrecommendations! Published in 2022 at "Bioactive Materials"
DOI: 10.1016/j.bioactmat.2021.10.046
Abstract: Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI), such as Erlotinib, have demonstrated remarkable efficacy in the treatment of non-small cell lung cancer (NSCLC) patients with mutated EGFR. However, the efficacy of EGFR-TKIs in… read more here.
Keywords: egfr wild; wild type; erlotinib egfr; nanotheranostic agent ... See more keywords
Challenging the Paradigm: EGFR wild-type benefit from an EGFR inhibitor in NSCLC
Sign Up to like & getrecommendations! Published in 2017 at "Cancer treatment and research"
DOI: 10.1016/j.ctarc.2017.02.005
Abstract: Erlotinib and gefitinib are first generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI). Afatinib is a second generation pan-Her EGFR TKI. All three TKIs have demonstrated superiority to chemotherapy in the first line… read more here.
Keywords: egfr mutation; egfr wild; type benefit; paradigm egfr ... See more keywords
Salvage anlotinib showed sustained efficacy in heavily pretreated EGFR wild-type lung adenocarcinoma
Sign Up to like & getrecommendations! Published in 2020 at "Medicine"
DOI: 10.1097/md.0000000000022707
Abstract: Abstract Rationale: Anlotinib has been proved to be effective in advanced refractory non-small cell lung cancer. Patient concerns: A 47-year-old female non-smoker was admitted due to persistent chest tightness for a month. Diagnoses: Epidermal growth… read more here.
Keywords: anlotinib; lung; lung adenocarcinoma; egfr wild ... See more keywords
The Impact of EGFR Mutation Status and Brain Metastasis for Non-Small Cell Lung Cancer Treated with Ramucirumab plus Docetaxel
Sign Up to like & getrecommendations! Published in 2020 at "Oncology"
DOI: 10.1159/000507050
Abstract: Objectives: Currently, combination therapy of ramucirumab (RAM) + docetaxel (DOC) must play a more important role as a second-line treatment. Epithelial growth factor receptor (EGFR) mutation accounts for around 50% of oncogenic driver mutations in… read more here.
Keywords: egfr mutation; mutation status; egfr wild; group ... See more keywords
EZH2 inhibitors reverse resistance to gefitinib in primary EGFR wild-type lung cancer cells
Sign Up to like & getrecommendations! Published in 2020 at "BMC Cancer"
DOI: 10.1186/s12885-020-07667-7
Abstract: Background Lung cancer is the leading cause of cancer-related deaths worldwide. Non-small cell lung cancer (NSCLC) is the most common type of lung cancer. In traditional anti-cancer therapy, epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors… read more here.
Keywords: egfr wild; ezh2 inhibitors; cancer; cell ... See more keywords
The serum activity of thioredoxin reductases 1 (TrxR1) is correlated with the poor prognosis in EGFR wild-type and ALK negative non-small cell lung cancer
Sign Up to like & getrecommendations! Published in 2017 at "Oncotarget"
DOI: 10.18632/oncotarget.23252
Abstract: Background The thioredxin reductases 1 (TrxR1) is one of the major antioxidant and redox regulators in mammalian cells. Studies have shown that TrxR1 is over expressed in many malignancy diseases. However, few studies have evaluated… read more here.
Keywords: serum trxr1; egfr wild; trxr1 activity; serum ... See more keywords
Assessing efficacy and safety of stereotactic body radiation therapy for oligometastatic non-small cell lung cancer with epidermal growth factor receptor (EGFR) wild type
Sign Up to like & getrecommendations! Published in 2021 at "Translational Cancer Research"
DOI: 10.21037/tcr-20-2772
Abstract: Background Stereotactic body radiation therapy (SBRT) is an emerging therapy for oligometastatic cancer. The aim of this study was to investigate the efficacy and safety of high-dose radiotherapy for primary and oligometastatic lesions in epidermal… read more here.
Keywords: cancer; wild type; therapy; egfr wild ... See more keywords